The output of Chinese active pharmaceutical ingredient reached 1.06 million tons in 2010 which ranks first in the world. The annual increasing rate is 8.05%. However, for some time in future, in the case of rising prices, and continue strengthen about environmental management, the industry's cost advantage will be no longer evidently. Chinese API industry has ushered in the best time to adjust.
From 2010 to 2015, there are nearly 400 international patents on drugs expire, mainly in the respiratory system drugs, endocrine and metabolic drugs, cardiovascular drugs, central nervous system drugs, respiratory system, digestive system drugs and other medication and several major areas. API China 2010 exports also verified this trend, the export growth in the top ten drugs in addition to endocrine and metabolic drugs, other types of products are listed.
Expired patent medicine, especially the ‘blockbuster’ drug patent expiration level, the development of bulk drug industry in China will provide new opportunities. In this opportunity, the API has a character is the largest enterprises can benefit from the basic conditions. So, how can the characteristics of their products as raw material medicine? For the trade, must have the characteristics of bulk drugs the following elements:
1 The pharmaceutical raw materials must be soon to reach the patents expire and on the world’s ‘blockbuster’ sales levels.
2 If the patent has not expired, manufacturers can avoid the patent must have the maturity of production technology;
3 Market in the countries where international norms for drug certification;
4 Certified manufacturer of bulk drugs formulations can be used to make preparations for its production and marketing application in Europe API source. Once the application is approved, pharmaceutical raw materials will become the fixed supplier, so as to maintain price stability.
It should be noted that not all of these drugs in the country which obtain the approval number of the products are special bulk drugs, even if they are successfully exported through various channels. Even with international certification documents, but without preparation of the bulk drugs specified manufacturers into regulating the market is still very difficult.
At present, China can be only regarded as API ‘production power’ rather than the production of power. Therefore, the country's industrial structure adjustment of industry will necessarily reflect on the development of bulk drugs glutathione .On the one hand it will increase research and development. On the other hand there will have on existing businesses regulation. In this process, inefficient and highly polluting enterprises will be merged, acquired or eliminated, and eventually several competitive large enterprises will be formed. Thereby it will increase the international competitiveness of Chinese pharmaceutical companies.
Source:http://www.cospcn.com